Table 2 Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users to new warfarin users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014
|  | Rivaroxaban User (n = 32,495) | Matched Warfarin User (n = 45,496) | Hazard Ratio (95% CI)a | p-value | ||||
|---|---|---|---|---|---|---|---|---|
Main outcomes | # Events | Person-years | IR (95% CI) | # Events | Person-years | IR (95% CI) | Â | Â |
 Ischemic stroke | 165 | 33,252 | 5.0 (4.3–5.8) | 347 | 45,965 | 7.5 (6.8–8.4) | 0.75 (0.62, 0.91) | 0.003 |
 Intracranial bleeding | 46 | 33,309 | 1.4 (1.0–1.8) | 124 | 45,958 | 2.7 (2.3–3.2) | 0.55 (0.39, 0.78) | 0.0008 |
 Myocardial infarction | 244 | 33,183 | 7.4 (6.5–8.3) | 421 | 45,965 | 9.2 (8.3–10.1) | 0.88 (0.75, 1.03) | 0.11 |
 Gastrointestinal bleeding | 492 | 33,134 | 14.8 (13.6–16.2) | 717 | 45,649 | 15.7 (14.6–16.9) | 1.07 (0.95, 1.20) | 0.29 |
Control outcomes | ||||||||
 Hip / pelvic fracture | 194 | 33,214 | 5.8 (5.1–6.7) | 408 | 45,866 | 8.9 (8.1–9.8) | 0.83 (0.70, 0.99) | 0.04 |
 Breast / prostate cancer | 272 | 33,236 | 8.2 (7.3–9.2) | 419 | 45,941 | 9.1 (8.3–10.0) | 0.92 (0.79, 1.08) | 0.33 |
 Asthma | 443 | 33,157 | 13.4 (12.2–14.6) | 606 | 45,769 | 13.2 (12.2–14.3) | 0.99 (0.88, 1.13) | 0.93 |